

WEST

LS5: Entry 7 of 16

File: PGPB

Jul 4, 2002

DOCUMENT-IDENTIFIER: US 20020086812 A1

TITLE: Methods and compositions for diagnosis and treatment of cancer

Detail Description Paragraph (217):

[0234] In one aspect, the therapeutic nucleic acid comprises a CaSm nucleic acid that is part of an expression vector that expresses a dominant non-functional CaSm protein or fragment or chimeric protein thereof in cancer cells. The function of CaSm is thought to be mediated by protein-protein interactions. Therefore, CaSm mutants that are defective in function but effective in binding to its interacting partner can be used as a dominant negative mutant to compete with the wild type CaSm. As a result, the normal interactions between a wild type CaSm and its cellular interacting partners are disrupted. Dominant non-functional CaSm can be engineered for expression in cancer cells that inappropriately overexpress CaSm.